Clobetasol: 6 agencies, 2006–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 20.2 years separate the first record, 21 Mar 2006 at AWMSG (Wales), from the most recent, 17 Jun 2026 at CIPM (Spain).
HAS (France) changed its position: not recommended on 17 Nov 2010, recommended by 20 Dec 2023, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 3 of 12 records date from 2023 or later.
3 distinct indication wordings are recorded for clobetasol by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 12 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess clobetasol, on 21 Mar 2006; CIPM (Spain) did not open a file until 17 Jun 2026 — an unusually long tail of 20.2 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 9 years in total.
HAS (France) is the only agency to have returned to clobetasol, recording 7 separate entries.
6 of the 18 agencies in this archive hold a record for clobetasol.
The full ledger for clobetasol reads 8 recommended, 2 other, 1 not recommended and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Corticosteroid responsive dermatoses | Recommended | source |
| CONITEC (Brazil) | 4 Oct 2012 | Tratamento da psoríase. | incorporated into SUS | source |
| HAS (France) | 3 Oct 2012 | Listing (Transparency Committee) | ASMR V | source |
| SMC (Scotland) | 11 Aug 2008 | Short course treatment of steroid-responsive dermatoses of the scalp such as psoriasis, which do not respond satisfactorily to less active steroids | accepted | source |
| AWMSG (Wales) | 21 Mar 2006 | Short course treatment of steroid-responsive dermatoses of the scalp, such as psoriasis, which do not respond to less ac… | outside AWMSG criteria | source |
7 further decisions for clobetasol, across 2 agencies, are not shown here. They include the most recent record on file, 17 Jun 2026 from CIPM (Spain); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- methylprednisolone — same ATC class D07A — Dermatological corticosteroids
- vutrisiran — also decided by CIPM in 2026Q2
- omalizumab — also decided by CIPM in 2026Q2
- azithromycin — also decided by CIPM in 2026Q2
- finerenone — also decided by CIPM in 2026Q2
- ibrutinib — also decided by CIPM in 2026Q2
Coverage: 12 decisions for clobetasol from 6 agencies, 2006 to 2026. Data to 7 Sep 2026. ATC class D07A — Dermatological corticosteroids. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.